* Sana Biotechnology Inc is expected to show no change in quarterly revenue when it reports results on November 6 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Sana Biotechnology Inc is for a loss of 27 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 2.5% in the last three months.
* Wall Street's median 12-month price target for Sana Biotechnology Inc is $13.00, above its last closing price of $4.66.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.28 -0.28 -0.32 Missed -12.3
Mar. 31 2024 -0.33 -0.32 -0.32 Met -0.6
Dec. 31 2023 -0.38 -0.38 -0.41 Missed -7.9
Sep. 30 2023 -0.43 -0.45 0.02 Beat 104.5
Jun. -0.42 -0.43 -0.59 Missed -38.3
30 2023
Mar. 31 2023 -0.42 -0.45 -0.43 Beat 3.7
Jan. 1 0001 -0.51 -0.51 -0.38 Beat 26.2
Sep. 30 2022 -0.53 -0.53 -0.45 Beat 15.1
This summary was machine generated August 9 at 11:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments